Skip to content

Oral minoxidil and spironolactone versus topical minoxidil for female pattern hair loss

Oral minoxidil and spironolactone versus topical minoxidil for female pattern hair loss

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
REBEC
Registry ID
RBR-6c26hx
Enrollment
Unknown
Registered
2017-01-09
Start date
2017-01-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female pattern hair loss

Interventions

A randomized, controlled, blind-eyed, parallel, monocentric, randomized, 24-week follow-up clinical trial involving 60 patients will be conducted. After signing the consent form (Annex 2) patients wil
Drug

Sponsors

Faculdade Medicina da Universidade Estadual Paulista - UNESP
Lead Sponsor
Faculdade Medicina da Universidade Estadual Paulista - UNESP
Collaborator

Eligibility

Sex/Gender
Female
Age
20 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients with female pattern hair loss; age between 20 and 55 years

Exclusion criteria

Exclusion criteria: Patients who had been treated for hair loss in the last 6 months, patients with hipertension, heart and kidney disease, patients with other causes of hair loss tha female pattern hair loss, patients in childbearing age who not using contraception;

Design outcomes

Primary

MeasureTime frame
Increased of hair count in an area of 2 cm² that will be clipped (leaving hairs with a length of 1 mm) in the parietal region (at the point of intersection of the sagittal midline with the line passing through pre-auricular region). Dermoscopic photo will be performed with Trichoscan® equipment. Using ImageJ® software, the area count will be counted before the start of treatment and after 6 months.

Secondary

MeasureTime frame
Secondary outcomes are not expected.

Countries

Brazil

Contacts

Public ContactPaulo Ramos

Faculdade Medicina da Universidade Estadual Paulista - UNESP

dermato.paulo@gmail.com+55 (43) 3256 9898

Outcome results

None listed

Source: REBEC (via WHO ICTRP)